| Literature DB >> 12189274 |
Abstract
This article comments upon the use of data mining tools to examine clinical data. Many cardiovascular patients have co-morbid diseases that put them at risk for polypharmacy, or severe adverse reactions from the interactions of multiple medications. Clinical trials typically use too few patients with stringent inclusion/exclusion criteria that prevent an examination of the issue of polypharmacy. However, clinical data collected in the course of patient treatment can be used in conjunction with data mining to find meaningful results.Entities:
Mesh:
Year: 2001 PMID: 12189274 DOI: 10.1385/ct:1:3:177
Source DB: PubMed Journal: Cardiovasc Toxicol ISSN: 1530-7905 Impact factor: 3.231